Abstracts Archive - Page 1120 of 2607 - ACR Meeting Abstracts

Abstract Number: 2699 • 2019 ACR/ARP Annual Meeting
Systemic Therapy in Children with Juvenile Idiopathic Arthritis-Associated Uveitis Immediately Following Failure of Methotrexate, Adalimumab and Infliximab
Najima Mwase ¹, Theresa Hennard ², Joseph McDonald ³, Amy Cassedy ⁴, Onengiya Harry ³ and Sheila Angeles-Han⁵, ¹Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Division of Rheumatology, Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, ³Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, ⁴Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, ⁵Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cinicinnati
Background/Purpose: Juvenile idiopathic arthritis-associated uveitis (JIA-U) is the most common extra-articular manifestation of JIA, leading to ocular complications and blindness when not adequately treated. First…
Abstract Number: 2700 • 2019 ACR/ARP Annual Meeting
Adalimumab Alone Is Superior to Adalimumab Plus Methotrexate in Juvenile Idiopathic Arthritis Associated Uveitis: Data from the ORCHIDEA Registry
Gabriele Simonini¹, Fabio Vittadello ², Francesca Tirelli ³, Maria Elisabetta Zannin ², Emanuela Del Giudice ⁴, Claudia Bracaglia ⁵, Serena Pastore ⁶, Mariolina Alessio ⁷, Angelo Ravelli ⁸, Francesco La Torre ⁹, Romina Gallizzi ¹⁰, Ilaria Maccora ¹¹ and Francesco Zulian ², ¹Rheumatology Unit Anna Meyer Children's Hospital NEUROFARBA Dpt University of Florence, Firenze, Italy, ²Department of Woman and Child Health, University of Padua, Italy, Padova, Italy, ³Post Graduate School of Pediatrics, University of Florence, Florence, Italy, Firenze, Italy, ⁴Department of Pediatrics, Sapienza University, Rome, Italy, Roma, Italy, ⁵Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ⁶Institute for Maternal and Child Health IRCCS "Burlo Garofolo," Trieste, Italy, Trieste, Italy, ⁷University Hospital Federico II, Naples, Napoli, Italy, ⁸IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genova, Italy, ⁹Rheumatology Unit, Giovanni XXIII Children’s Hospital, Bari, Italy, Bari, Italy, ¹⁰Azienda Ospedaliera Universitaria Gaetano Martino, Messina, Messina, Italy, ¹¹Post Graduate School of Pediatrics, University of Florence, Florence, Italy, Florence, Toscana, Italy
Background/Purpose: To compare the efficacy and safety of Adalimumab alone (ADA) versus ADA in combination with Methotrexate (ADA-MTX) in an open-label, retrospective, comparative, multicentre cohort…
Abstract Number: 2701 • 2019 ACR/ARP Annual Meeting
Frequency of Juvenile Idiopathic Arthritis (JIA) Subgroups and JIA-associated Uveitis Among JIA Patients Admitted to Referral Pediatric Rheumatology Clinics In TurkEy: A Retrospective Study, JUPITER
Sezgin Sahin ¹, Ceyhun Acari ², Hafize Emine Sonmez ³, Fatma Zehra Kilic ⁴, Erdal Sag ⁵, Hatice Adiguzel Dundar ⁶, Amra Adrovic ⁷, Selcan Demir ³, Kenan Barut ⁸, Yelda Bilginer ⁹, Betul Sozeri ¹⁰, Erbil Unsal ⁶, Seza Ozen ¹¹ and Ozgur Kasapcopur¹², ¹Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, Istanbul, Istanbul, Turkey, ²Dokuz Eylul University, School of Medicine, Izmir, Turkey, ³Hacettepe University, School of Medicine, Ankara, Turkey, ⁴Umraniye Training and Research Hospital, Istanbul, ⁵Hacettepe University, Ankara, Turkey, ⁶Dokuz Eylul University, School of Medicie, Izmir, Turkey, ⁷Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, Istanbul, Turkey, ⁸Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, İstanbul, Istanbul, Turkey, ⁹Division of Pediatric Rheumatology, Department of Pediatrics, Hacettepe University, Ankara, Turkey, ¹⁰University of Health Sciences , Umraniye Tranining and Research Hospital Division of Pediatric Rheumatology, Istanbul, Turkey, Istanbul, Turkey, ¹¹Hacettepe University Hospital, Ankara, Turkey, ¹²Department of Pediatric Rheumatology, Istanbul University-Cerrahpasa, Istanbul, Turkey, Istanbul, Turkey
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is a chronic childhood arthritis with onset before age of 16 and has a significant degree of morbidity that negatively…
Abstract Number: 2702 • 2019 ACR/ARP Annual Meeting
Patients’ and Parents’ Perception of Disease and Its Impact on Life in Juvenile Idiopathic Arthritis: Results from Multinational Virtual Focus Groups by the OMERACT JIA Working Group
Alessandra Alongi¹, Serana Calandra ¹, Susan Thornhill ², Jennifer Stinson ³, Jen Horonjeff ⁴, Daniel Horton ⁵, Alessandro Consolaro ⁶ and Esi Morgan ⁷, ¹Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy and IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, Genoa, Italy, Genoa, ²Thornhill Associates, Hermosa Beach, USA, Hermosa Beach, ³The Hospital for Sick Children, and University of Toronto, Toronto, Canada, Toronto, ⁴Columbia University Medical Center, New York, USA, New York, ⁵Division of Pediatric Rheumatology, Department of Pediatrics, Rutgers Robert Wood Johnson Medical School, Institute for Health, Health Care Policy and Aging Research, Rutgers Biomedical and Health Sciences, New Brunswick, ⁶Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy and IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, Genoa, Italy, Genova, Italy, ⁷Cincinnati Children’s Hospital, University of Cincinnati, Cinncinati, OH
Background/Purpose: The OMERACT Juvenile Idiopathic Arthritis Core Set Working Group formed in 2015 as an international initiative to revise the existing Core Set with relevant…
Abstract Number: 2704 • 2019 ACR/ARP Annual Meeting
Injection Fear in Juvenile Idiopathic Arthritis Patients Using Injectable Medications
Kathleen Collins¹, Anava Wren ² and Tzielan Lee ², ¹Stanford University School of Medicine, Palo Alto, CA, ²Stanford University School of Medicine, Palo Alto
Background/Purpose: Injectable medications are frequently used to treat Juvenile Idiopathic Arthritis (JIA). Fear of pain and needle fear have been identified as barriers to injectable…
Abstract Number: 2705 • 2019 ACR/ARP Annual Meeting
Profiling Behavioral and Psychological Symptoms in Children with Spondyloarthritis and Polyarthritis
Anne McHugh¹, Avis Chan ², Carolyn Herrera ², Margo Thienemann ² and Jennifer Frankovich ², ¹Stanford University School of Medicine, Palo Alto, CA, ²Stanford University School of Medicine, Palo Alto
Background/Purpose: Mental health disorders are thought to be common in patients with rheumatic disease, but studies examining behavioral issues in patients with juvenile idiopathic arthritis…
Abstract Number: 2706 • 2019 ACR/ARP Annual Meeting
Association of Body Mass Index with Juvenile Idiopathic Arthritis Disease Activity: A Portuguese and Brazilian Collaborative Analysis with Data from Reuma.pt Registry
Agna Neto¹, Ana Filipa Mourão ², Filipa Oliveira-Ramos ³, Raquel Marques ³, Paula Estanqueiro ⁴, Manuel Salgado ⁴, Margarida Guedes ⁵, Daniela Piotto ⁶, Clovis Artur Silva ⁷, José Melo Gomes ⁸, Marta Cabral ⁹, Marta Conde ¹⁰, Ricardo Figueira ¹¹, Maria José Santos ¹², João Eurico Fonseca ¹³, Maria Teresa Terreri ⁶ and Helena Canhão ¹⁴, ¹Rheumatology Department, Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental; CEDOC, NOVA Medical School, Faculdade de Ciências Médicas, Lisbon; Hospital Central do Funchal, Madeira., Lisbon, Portugal, ²Rheumatology Department, Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental; CEDOC, NOVA Medical School, Faculdade de Ciências Médicas, Lisbon, Lisbon, Portugal, ³Rheumatology and Metabolic Bone Diseases, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte; Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisbon, Lisbon, Portugal, ⁴Pediatrics, Hospital Pediátrico Carmona da Mota, Coimbra, Coimbra, Portugal, ⁵Unidade de Imunologia Clínica, Centro Hospitalar Universitário do Porto, Porto, Portugal, ⁶Pediatric Rheumatology Unit, Universidade Federal de São Paulo, São Paulo, Brazil, ⁷Universidade de São Paulo, São Paulo, Brazil, ⁸Instituto Português de Reumatologia; Clínica Dr. Melo Gomes, Lisbon., Lisbon, Portugal, ⁹Pediatrics, Hospital Prof. Doutor Fernando Fonseca, Lisbon, Lisbon, Portugal, ¹⁰Pediatric Rheumatology Unit, Hospital Dona Estefânia, Centro Hospitalar de Lisboa Central, Lisbon, Lisbon, Portugal, ¹¹Rheumatology Department, Hospital Central do Funchal, Funchal, Madeira, Portugal, ¹²Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, ¹³Rheumatology and Bone Diseases Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte; Unidade de Investigação em Reumatologia, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa; Centro Académico de Medicina de Lisboa; Lisbon, Portugal., Lisbon, Portugal, ¹⁴CEDOC, EpiDoC Unit, NOVA Medical School, Lisbon, Lisbon, Portugal
Background/Purpose: In adults with Rheumatoid Arthritis, obesity has been associated with higher disease activity. However, in Juvenile Idiopathic Arthritis (JIA), the influence of body mass…
Abstract Number: 2707 • 2019 ACR/ARP Annual Meeting
Improvement in Patient-Reported Outcomes in Patients Aged 2–5 Years with Polyarticular-Course JIA Treated with Subcutaneous Abatacept: 2-Year Results from a Phase III International Study
Hermine Brunner¹, Nikolay Tzaribachev ², Ingrid Louw ³, Jordi Antón ⁴, Diego Viola ⁵, Bernard Lauwerys ⁶, Rubèn J Cuttica ⁷, Pierre Quartier ⁸, Elisabeth Gervais ⁹, Alexandre Belot ¹⁰, Kirsten Minden ¹¹, Thomas Lutz ¹², Rolando Cimaz ¹³, Mahmood M. T. M. Ally ¹⁴, Riana van Zyl ¹⁵, Inmaculada Calvo Penadés ¹⁶, Joe Zhuo ¹⁷, Robert Wong ¹⁸, Marleen Nys ¹⁹, Yedid Elbez ²⁰, Alberto Martini ²¹, Daniel J. Lovell ²² and Nicolino Ruperto ²³, ¹Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Pediatric Rheumatology Research Institute, Bad Bramstedt, Germany, ³Panorama Medical Centre, Parow, South Africa, ⁴Hospital Sant Joan de Déu, Barcelona, Spain, ⁵CAICI Institute, Rosario City, Santa Fe State, Argentina, ⁶Rheumatology, Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, Brussels, Belgium, ⁷Hospital General de Niños Pedro de Elizalde, Buenos Aires, Argentina, ⁸Necker Hospital, Paris, France, ⁹CHU de Poitiers, Rheumatology, Poitiers, France, ¹⁰Centre Hospitalier Universitaire de Lyon, Lyon, France, ¹¹German Rheumatism Research Center and Charité University Medicine, Berlin, Germany, ¹²Heidelberg University Hospital, Heidelberg, Germany, ¹³Meyer Children's Hospital in Florence, Florence, Italy, ¹⁴University of Pretoria, Pretoria, South Africa, ¹⁵University of the Free State, Bloemfontein, South Africa, ¹⁶Hospital Univ. La Fe, Valencia, Spain, ¹⁷Bristol-Myers Squibb, Princeton, NJ, ¹⁸Bristol-Myers Squibb, Princeton, ¹⁹Bristol-Myers Squibb, Braine L’Alleud, Belgium, ²⁰Excelya, Boulogne-Billancourt, France, ²¹IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genova, Italy, ²²Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, ²³Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy
Background/Purpose: Efficacy of SC abatacept in patients with polyarticular-course JIA (pJIA) was shown in a 2-year, open-label, Phase III international study (NCT01844518).1 Pediatric patient-reported outcomes…
Abstract Number: 2708 • 2019 ACR/ARP Annual Meeting
Effect of Immunogenicity on Efficacy and Safety of Subcutaneous or Intravenous Abatacept in Pediatric Patients with Polyarticular-Course JIA: Findings from Two Phase III Trials
Hermine Brunner¹, Nikolay Tzaribachev ², Ingrid Louw ³, Alberto Berman ⁴, Inmaculada Calvo Penadés ⁵, Jordi Antón ⁶, Francisco Ávila-Zapata ⁷, Rubèn J Cuttica ⁸, Gerd Horneff ⁹, Robert Wong ¹⁰, Mehmooda Shaikh ¹¹, Johanna Mora ¹¹, Marleen Nys ¹², Daniel J. Lovell ¹³, Alberto Martini ¹⁴ and Nicolino Ruperto ¹⁵, ¹Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Pediatric Rheumatology Research Institute, Bad Bramstedt, Germany, ³Panorama Medical Centre, Parow, South Africa, ⁴Universidad Nacional de Tucuman and Centro Médico Privado de Reumatología, Tucuman, Argentina, ⁵Hospital Univ. La Fe, Valencia, Spain, ⁶Hospital Sant Joan de Déu, Barcelona, Spain, ⁷Star Medica Hospital, Merida, Yucatán, Mexico, ⁸Hospital General de Niños Pedro de Elizalde, Buenos Aires, Argentina, ⁹Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ¹⁰Bristol-Myers Squibb, Princeton, ¹¹Bristol-Myers Squibb, Princeton, NJ, ¹²Bristol-Myers Squibb, Braine L’Alleud, Belgium, ¹³Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, ¹⁴IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genova, Italy, ¹⁵Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy
Background/Purpose: Patients (pts) with polyarticular-course JIA (pJIA) may develop anti-drug antibodies (ADAs) in response to biologics.1 Presence of ADAs has been associated with treatment (tmt)…
Abstract Number: 2709 • 2019 ACR/ARP Annual Meeting
Secukinumab Is a Promising Treatment for Patients with Juvenile Enthesitis Related Arthritis Nonresponsive to Anti-TNF Treatment According the Juvenile Spondyloarthritis Disease Activity Index
Ivan Foeldvari¹ and Jean Baer ¹, ¹Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany
Background/Purpose: Secukinumab (SEC) is licensed to treat adults with spondyloarthritis and psoriatic arthritis. It is not licensed for juvenile patients yet. As biologic agents up…
Abstract Number: 2710 • 2019 ACR/ARP Annual Meeting
Sarilumab, a Human Monoclonal Antibody to the Interleukin-6 Receptor, in Polyarticular-course Juvenile Idiopathic Arthritis: A 12-week, Multinational, Open-label, Dose-finding Study
Fabrizio De Benedetti¹, Inmaculada Calvo Penadés ², Nadina Rubio-Pérez ³, Alexey Maschan ⁴, Pierre Quartier ⁵, Zbigniew Żuber ⁶, Marina Stanislav ⁷, Raul Barria ⁸, Daniel Clemente ⁹, Gabriel Vega-Cornejo ¹⁰, Nancy Liu ¹¹, Christine Xu ¹¹, Angeliki Giannelou ¹², Bolanle Akinlade ¹² and Lydie Baret-Cormel ¹³, ¹Bambino Gesù Children’s Hospital, Rome, Italy, ²Hospital Univ. La Fe, Valencia, Spain, ³University Hospital Dr. José Eleuterio González, Monterrey, Mexico, ⁴Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia, ⁵Necker Hospital, Paris, France, ⁶Andrzej Frycz Modrzewski Krakow University, Kraków, Poland, ⁷V.A. Nasonova Research Rheumatology Institute, Moscow, Russia, ⁸Bioreuma, Concepción, Chile, ⁹Hospital Infantil Universitario Niño Jesús, Madrid, Spain, ¹⁰CREA de Guadalajara, Jalisco, Mexico, ¹¹Sanofi, Bridgewater, NJ, ¹²Regeneron, New York, NY, ¹³Sanofi, Chilly-Mazarin, France
Background/Purpose: Sarilumab blocks interleukin-6 (IL-6) from binding to membrane and soluble IL-6 receptor-α. Sarilumab is approved for adults with rheumatoid arthritis (RA) and is being…
Abstract Number: 2711 • 2019 ACR/ARP Annual Meeting
Utilization of Biologic Treatments in Oligoarticular and Polyarticular Juvenile Idiopathic Arthritis
Daniah Basodan¹, Kathleen M Andersen ², Xintong Li ³, Jeffrey Curtis ⁴ and G. Caleb Alexander ⁵, ¹University of Alberta, Edmonton, AB, Canada, ²Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health,, Baltimore, MD, ³Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Johns Hopkins Bloomberg School of Public Health. Center for Drug Safety and Effectiveness, Baltimore, MD
Background/Purpose: In recent years, juvenile idiopathic arthritis (JIA) treatment options have expanded to include biologics such as tumor necrosis factor inhibitors (TNFi) and non-TNF inhibitors…
Abstract Number: 2712 • 2019 ACR/ARP Annual Meeting
Patterns of Etanercept Use in the Childhood Arthritis and Rheumatology Research Alliance Juvenile Idiopathic Arthritis Registry
Natalie Shiff¹, Aimee Lougee ², Roland Matsouaka ², David Collier ³, Yukiko Kimura ⁴, Dax Rumsey ⁵, Jennifer Schenfeld ⁶, Scott Stryker ³, Marinka Twilt ⁷ and Timothy Beukelman ⁸, ¹University of Florida, Gainesville, FL, ²Duke University, Durham, NC, ³Amgen Inc., Thousand Oaks, CA, ⁴Joseph M Sanzari Children's Hospital, Hackensack University Medical Center, Cincinnati, OH, ⁵University of Alberta, Edmonton, AB, Canada, ⁶Amgen, Inc, Thousand Oaks, CA, ⁷University of Calgary, Calgary, AB, Canada, ⁸University of Alabama Birmingham, Birmingham, AL
Background/Purpose: Etanercept (ETN) is an anti-tumor necrosis factor (anti-TNF) therapy that is FDA approved for the treatment of polyarticular juvenile idiopathic arthritis (JIA). This study…
Abstract Number: 2713 • 2019 ACR/ARP Annual Meeting
Juvenile Spondyloarthritis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: High Biologic Use, Low Prevalence of HLA-B27, and Equal Sex Representation in Those with Sacroiliitis
Dax Rumsey¹, Aimee Lougee ², Roland Matsouaka ², David Collier ³, Laura Schanberg ⁴, Jennifer Schenfeld ⁵, Natalie Shiff ⁶, Matthew Stoll ⁷, Scott Stryker ³, Pamela F. Weiss ⁸ and Timothy Beukelman ⁹, ¹University of Alberta, Edmonton, AB, Canada, ²Duke University, Durham, NC, ³Amgen Inc., Thousand Oaks, CA, ⁴Duke University Medical Center, Durham, NC, ⁵Amgen, Inc, Thousand Oaks, CA, ⁶University of Florida, Gainesville, FL, ⁷University of Alabama at Birmingham, Birmingham, AL, ⁸Children's Hospital of Philadelphia, Philadelphia, PA, ⁹University of Alabama Birmingham, Birmingham, AL
Background/Purpose: Herein we describe characteristics of children with juvenile spondyloarthritis (JSpA, i.e. enthesitis-related arthritis [ERA] or juvenile psoriatic arthritis [JPsA]) enrolled in the Childhood Arthritis…
Abstract Number: 2714 • 2019 ACR/ARP Annual Meeting
Investigation of Inactive Disease Activity States Among JIA Patients in the CARRA Registry
Melissa Mannion¹, Fenglong Xie ² and Timothy Beukelman ³, ¹University of Alabama at Birmingham, Alabama, ²University of Alabama at Birmingham, Birmingham, ³University of Alabama Birmingham, Birmingham, AL
Background/Purpose: Inactive disease is the stated goal of treatment in juvenile idiopathic arthritis (JIA) and is typically measured by a composite score that combines several…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].